Developer docs
API playgroundTry for free, no card

Search company profiles

Nira Biosciences

Full company profile

uuid000cw6t

Namestring
Nira Biosciences
Legal namestring
Nira Biosciences
Websiteurl
nirabio.com
Company typeenum
Private
Founded yearstring
-
Short descriptiontext

Nira Biosciences is a biotechnology subsidiary of Alys Pharmaceuticals developing an antibody-targeted photo-immunotherapy platform for treating inflammatory skin disorders, serving dermatology patients and providers.

Operating statusenum
Acquired
Ownership categoryenum
akta.pro rankint
Markets served

Serves global market

Keyword5 values
photo-immunotherapy treatments, antibody-targeted therapeutics, inflammatory skin disorders, biotechnology platform, dermatology therapeutics
Industry4 codes
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Dermatology Therapeutics
No data
Cost components2 values
Technology or R&D, Personnel
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Nira Biosciences develops a biotechnology platform for antibody-targeted photo-immunotherapy treatments aimed at inflammatory skin disorders. The platform combines antibody targeting with photo-immunotherapy to deliver therapeutic intervention for dermatologic inflammatory conditions. As a fully owned subsidiary of Alys Pharmaceuticals, the company focuses on advancing this single-indication dermatology therapeutic platform rather than selling commercialized end products.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Antibody-targeted photo-immunotherapy platform
CategoryDermatology Therapeutics
Description

A biotechnology platform combining antibody targeting with photo-immunotherapy for the treatment of inflammatory skin disorders, positioned for healthcare providers and pharmaceutical partners in dermatology therapeutics.

Partnership1 partner
Strategic tierCoreTypeOthers
Description

Nirabio is now a fully owned subsidiary of Alys Pharmaceuticals. The company maintains its identity as Nirabio while operating under the Alys Pharmaceuticals corporate umbrella.

Peers10 records
TypeDirect peer
Description

AnaptysBio is an immunology-focused biotechnology company developing antibody therapeutics for inflammatory and autoimmune diseases. It is comparable to Nira as an antibody-platform biotech targeting inflammation, with overlapping therapeutic areas in dermatology and immunology.

TypeEmerging player
Description

Dermavant is a specialty biopharmaceutical company developing treatments for inflammatory skin diseases, including novel topical and systemic therapies. It is comparable to Nira as a focused emerging player in inflammatory dermatology, though it relies on more conventional modalities.

TypeBroad incumbent
Description

Amgen markets Otezla and Tezspire and has a broader inflammation pipeline including antibodies relevant to atopic dermatitis and other skin conditions. It is comparable as a broad incumbent antibody developer with overlapping inflammatory skin disease ambitions.

TypeDirect peer
Description

Alys Pharmaceuticals is the parent company that has fully acquired Nira Biosciences. It is directly comparable because it operates in the same antibody-targeted photo-immunotherapy space for inflammatory skin disorders and is the entity through which Nira's assets are now being advanced.

TypeBroad incumbent
Description

Sanofi, with Regeneron, markets Dupixent, the leading biologic for atopic dermatitis and other inflammatory skin and respiratory conditions. It is comparable as the dominant incumbent in antibody-based inflammatory skin therapeutics and defines the competitive benchmark Nira must beat.

TypeDirect peer
Description

Union Therapeutics is a biotechnology company developing innovative treatments for inflammatory skin diseases including atopic dermatitis. It is comparable to Nira as a specialty biotech focused specifically on novel mechanisms for inflammatory skin disorders.

TypeBroad incumbent
Description

AbbVie markets Rinvoq (JAK inhibitor) and Skyrizi (anti-IL-23) for inflammatory skin diseases including psoriasis and atopic dermatitis. It is comparable as a broad incumbent immunology company whose dermatology franchise sets the standard-of-care against which Nira's platform would compete.

TypeDirect peer
Description

MoonLake is a clinical-stage immunology biotech developing biologic therapies (e.g., sonelokimab) for inflammatory skin and joint diseases. It is comparable to Nira as a focused inflammation dermatology biotech building differentiated therapeutic platforms for skin disorders.

9Novartis (Cosentyx)
TypeBroad incumbent
Description

Novartis markets Cosentyx (secukinumab), an anti-IL-17 antibody widely used in psoriasis and other inflammatory skin conditions. It is comparable as a broad incumbent with a large antibody franchise in inflammatory dermatology.

TypeBroad incumbent
Description

Eli Lilly has been active in inflammatory skin disease therapeutics, including Olumiant (baricitinib) and the lebrikizumab anti-IL-13 program for atopic dermatitis. It is comparable as a large incumbent developing antibody-based therapeutics in the same inflammatory dermatology space.

Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nira Biosciences

Dermatology Therapeuticsnirabio.com

Nira Biosciences is a biotechnology subsidiary of Alys Pharmaceuticals developing an antibody-targeted photo-immunotherapy platform for treating inflammatory skin disorders, serving dermatology patients and providers.

Nira Biosciences firmographics

Firmographics
Name
Nira Biosciences
Legal name
Nira Biosciences
Website
https://nirabio.com
Company type
Private
Operating status
Acquired
Short description
Nira Biosciences is a biotechnology subsidiary of Alys Pharmaceuticals developing an antibody-targeted photo-immunotherapy platform for treating inflammatory skin disorders, serving dermatology patients and providers.
Ownership category
akta.pro rank

Nira Biosciences industry classification

Industry
Product category
Dermatology Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals

Keywords

  • Photo-immunotherapy treatments
  • Antibody-targeted therapeutics
  • Inflammatory skin disorders
  • Biotechnology platform
  • Dermatology therapeutics

Nira Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel

Nira Biosciences product offering

Product offering

Core offering

Nira Biosciences develops a biotechnology platform for antibody-targeted photo-immunotherapy treatments aimed at inflammatory skin disorders. The platform combines antibody targeting with photo-immunotherapy to deliver therapeutic intervention for dermatologic inflammatory conditions. As a fully owned subsidiary of Alys Pharmaceuticals, the company focuses on advancing this single-indication dermatology therapeutic platform rather than selling commercialized end products.

Differentiator

Problem solved

Functional benefit

Products and services

  • Antibody-targeted photo-immunotherapy platform A biotechnology platform combining antibody targeting with photo-immunotherapy for the treatment of inflammatory skin disorders, positioned for healthcare providers and pharmaceutical partners in dermatology therapeutics.

Companies that use Nira Biosciences

Customer profile

Segments1 record

Ideal customer profiles1 record

Nira Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Nira Biosciences partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Alys PharmaceuticalscoreOthersNirabio is now a fully owned subsidiary of Alys Pharmaceuticals. The company maintains its identity as Nirabio while operating under the Alys Pharmaceuticals corporate umbrella.

Nira Biosciences competitors and assessment

Company assessment

Direct peers

  • AnaptysBio: AnaptysBio is an immunology-focused biotechnology company developing antibody therapeutics for inflammatory and autoimmune diseases. It is comparable to Nira as an antibody-platform biotech targeting inflammation, with overlapping therapeutic areas in dermatology and immunology.
  • Alys Pharmaceuticals: Alys Pharmaceuticals is the parent company that has fully acquired Nira Biosciences. It is directly comparable because it operates in the same antibody-targeted photo-immunotherapy space for inflammatory skin disorders and is the entity through which Nira's assets are now being advanced.
  • Union Therapeutics: Union Therapeutics is a biotechnology company developing innovative treatments for inflammatory skin diseases including atopic dermatitis. It is comparable to Nira as a specialty biotech focused specifically on novel mechanisms for inflammatory skin disorders.
  • MoonLake Immunotherapeutics: MoonLake is a clinical-stage immunology biotech developing biologic therapies (e.g., sonelokimab) for inflammatory skin and joint diseases. It is comparable to Nira as a focused inflammation dermatology biotech building differentiated therapeutic platforms for skin disorders.

Emerging players

  • Dermavant Sciences: Dermavant is a specialty biopharmaceutical company developing treatments for inflammatory skin diseases, including novel topical and systemic therapies. It is comparable to Nira as a focused emerging player in inflammatory dermatology, though it relies on more conventional modalities.

Broad incumbents

  • Amgen: Amgen markets Otezla and Tezspire and has a broader inflammation pipeline including antibodies relevant to atopic dermatitis and other skin conditions. It is comparable as a broad incumbent antibody developer with overlapping inflammatory skin disease ambitions.
  • Sanofi (Dupixent / anti-IL-4Rα franchise): Sanofi, with Regeneron, markets Dupixent, the leading biologic for atopic dermatitis and other inflammatory skin and respiratory conditions. It is comparable as the dominant incumbent in antibody-based inflammatory skin therapeutics and defines the competitive benchmark Nira must beat.
  • AbbVie (Rinvoq / Skyrizi): AbbVie markets Rinvoq (JAK inhibitor) and Skyrizi (anti-IL-23) for inflammatory skin diseases including psoriasis and atopic dermatitis. It is comparable as a broad incumbent immunology company whose dermatology franchise sets the standard-of-care against which Nira's platform would compete.
  • Novartis (Cosentyx): Novartis markets Cosentyx (secukinumab), an anti-IL-17 antibody widely used in psoriasis and other inflammatory skin conditions. It is comparable as a broad incumbent with a large antibody franchise in inflammatory dermatology.
  • Eli Lilly (Olumiant / lebrikizumab program): Eli Lilly has been active in inflammatory skin disease therapeutics, including Olumiant (baricitinib) and the lebrikizumab anti-IL-13 program for atopic dermatitis. It is comparable as a large incumbent developing antibody-based therapeutics in the same inflammatory dermatology space.

Market position

Customer concentration

Nira Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nira Biosciences leadership team

Management profile

Number of profiles

Profiles1 record

Nira Biosciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nira Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nira Biosciences

What does Nira Biosciences do?

Nira Biosciences develops a biotechnology platform for antibody-targeted photo-immunotherapy treatments aimed at inflammatory skin disorders. The platform combines antibody targeting with photo-immunotherapy to deliver therapeutic intervention for dermatologic inflammatory conditions. As a fully owned subsidiary of Alys Pharmaceuticals, the company focuses on advancing this single-indication dermatology therapeutic platform rather than selling commercialized end products.

Is Nira Biosciences a public or private company?

Nira Biosciences is a private company. It is classified as corporate owned and is currently acquired.

When was Nira Biosciences founded?

Nira Biosciences was founded in -1.

Who are Nira Biosciences's main competitors?

Direct peers on record are AnaptysBio, Alys Pharmaceuticals, Union Therapeutics and MoonLake Immunotherapeutics. Dermavant Sciences is listed as an emerging player. Broad incumbents are Amgen, Sanofi (Dupixent / anti-IL-4Rα franchise), AbbVie (Rinvoq / Skyrizi), Novartis (Cosentyx) and Eli Lilly (Olumiant / lebrikizumab program).

Does Nira Biosciences have an API?

No public API is recorded for Nira Biosciences.

What industry is Nira Biosciences in?

Nira Biosciences's product category is Dermatology Therapeutics. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales